Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease

CardioVascular and Interventional Radiology

Volumn 40, Issue 4, 2017, Pages 496-501

  Young, Shamar ^a   D’Souza, Donna ^a   Flanagan, Siobhan ^a   Golzarian, Jafar ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Colon cancer; Drug elutting beads; Transarterial chemoembolization (TACE)

Indexed keywords

IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL LIVER METASTASIS; DRUG DELIVERY DEVICE; DRUG ELUTING BEAD; DRUG USE; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; SECONDARY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 85006998513     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-016-1537-5     Document Type: Article

References (25)

1. Welch JP, Donaldson GA. The clinical correlation of autopsy study of recurrent colorectal cancer. Ann Surg. 1979;189:496–502.
2. Silverberg E. Cancer statistics, 1977. CA Cancer J Clin. 1977;27:26–41.
3. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.
4. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.
5. Fong Y. Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy. Adv Surg. 2000;34:351–81.
6. Sinicrope A, Okamoto K, Kasi PM, Kawakami H. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016;14(5):651–8.
7. Ohhara Y, Fukuda N, Takeuchi S, et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol. 2016;8(9):642–55.
8. Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1–10.
9. Martin RC 2nd, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unrespectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinectics and phase I trial. J Gastrointest Surg. 2012;16(8):1531–8.
10. Martinc RC 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.
11. Fiorentini G, Aliberti C, Sarti D, et al. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrintest Oncol. 2015;7(6):47–54.
12. Akiwande O, Miller A, Hayes D, O’Hara R, Tomalty D, Martin RC. Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res. 2014;34(12):723–7245.
13. Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421–28.
14. Lencioni R, Aliberti C, de Baere T, et al. Transartrial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014;25(3):365–9.
15. Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Marin RC. Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Interv Radiol. 2015;38(2):361–71.
16. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.
17. Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009;2009:539795.
18. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8.
19. Bhutiani N, Akinwande O, Martin RC 2nd, Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016;40(5):1178–90.
20. Akinwande O, Scoggins C, Martin RC. Early experience with 70–150 µm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res. 2016;36(7):3413–8.
21. Eichler K, Zangos S, Mack MG, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). J Oncol. 2012;41(4):1213–20.
22. Iezzi R, Marisico VA, Guerra A, et al. Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase II single-center study. Cardiovasc Inerv Radiol. 2015;38(6):1523–31.
23. ®, drug-luting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31(12):4581–7.
24. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res. 2013;33(5):2077–83.
25. Abdalla EK, Bauer TW, Chun YS, D’Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB(Oxford). 2013;15(2):119–30.